Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience

Blood. 2015 Nov 12;126(20):2345-7. doi: 10.1182/blood-2015-08-662726. Epub 2015 Oct 6.

Authors

Vaishali Sanchorawala¹, Fangui Sun², Karen Quillen¹, J Mark Sloan¹, John L Berk³, David C Seldin¹

Affiliations

¹ Section of Hematology-Oncology and Amyloidosis Center, Boston University School of Medicine, Boston, MA.
² Amyloidosis Center, Boston University School of Medicine, and Department of Biostatistics, Boston University School of Public Health, Boston, MA.
³ Amyloidosis Center, Boston University School of Medicine, Boston, MA.

PMID: 26443620
DOI: 10.1182/blood-2015-08-662726

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Amyloidosis / mortality*
Amyloidosis / therapy*
Female
Follow-Up Studies
Humans
Male
Melphalan / administration & dosage*
Middle Aged
Stem Cell Transplantation*

Substances

Melphalan